Mount Yale Investment Advisors LLC Has $2.90 Million Stock Position in Novo Nordisk A/S (NYSE:NVO)

Mount Yale Investment Advisors LLC lessened its stake in Novo Nordisk A/S (NYSE:NVO) by 16.6% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 33,708 shares of the company’s stock after selling 6,725 shares during the quarter. Mount Yale Investment Advisors LLC’s holdings in Novo Nordisk A/S were worth $2,900,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also made changes to their positions in the company. Union Bancaire Privee UBP SA acquired a new stake in Novo Nordisk A/S in the fourth quarter valued at $746,000. Blue Trust Inc. lifted its stake in Novo Nordisk A/S by 34.6% in the 4th quarter. Blue Trust Inc. now owns 30,567 shares of the company’s stock valued at $2,629,000 after purchasing an additional 7,864 shares during the last quarter. PFG Investments LLC grew its holdings in Novo Nordisk A/S by 8.4% during the fourth quarter. PFG Investments LLC now owns 17,924 shares of the company’s stock worth $1,542,000 after purchasing an additional 1,389 shares during the period. Strategic Investment Advisors MI increased its position in Novo Nordisk A/S by 5.0% during the fourth quarter. Strategic Investment Advisors MI now owns 7,605 shares of the company’s stock worth $654,000 after buying an additional 360 shares during the last quarter. Finally, Empirical Financial Services LLC d.b.a. Empirical Wealth Management raised its stake in Novo Nordisk A/S by 8.4% in the fourth quarter. Empirical Financial Services LLC d.b.a. Empirical Wealth Management now owns 7,453 shares of the company’s stock valued at $641,000 after buying an additional 578 shares during the period. 11.54% of the stock is owned by institutional investors.

Novo Nordisk A/S Stock Up 8.4 %

Shares of NVO opened at $87.94 on Monday. The company has a current ratio of 0.94, a quick ratio of 0.75 and a debt-to-equity ratio of 0.43. Novo Nordisk A/S has a 12 month low of $78.17 and a 12 month high of $148.15. The firm’s 50 day moving average is $95.35 and its 200-day moving average is $114.80. The stock has a market capitalization of $394.65 billion, a PE ratio of 28.46, a P/E/G ratio of 0.90 and a beta of 0.45.

Analyst Ratings Changes

Several research analysts have recently commented on NVO shares. BNP Paribas upgraded Novo Nordisk A/S to a “strong-buy” rating in a research note on Monday, December 2nd. Cantor Fitzgerald reissued an “overweight” rating and issued a $160.00 price objective on shares of Novo Nordisk A/S in a research report on Wednesday, November 6th. BMO Capital Markets reduced their target price on shares of Novo Nordisk A/S from $156.00 to $105.00 and set an “outperform” rating for the company in a report on Monday, December 23rd. Sanford C. Bernstein raised shares of Novo Nordisk A/S from an “underperform” rating to a “market perform” rating in a report on Monday, January 6th. Finally, UBS Group raised Novo Nordisk A/S from a “sell” rating to a “buy” rating in a research report on Wednesday, January 8th. One analyst has rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, Novo Nordisk A/S currently has an average rating of “Buy” and a consensus price target of $145.25.

About Novo Nordisk A/S

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.